TrialRheumatology (Oxford, England)2025

Ozoralizumab shows effectiveness regardless of baseline RF and ACPA titres in patients with RA: a post hoc analysis of the OHZORA trial.

Ryu Watanabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.